MSFT 424.41 -0.7251% AAPL 229.52 -2.688% NVDA 139.094 -3.1311% GOOGL 162.48 -1.6108% GOOG 164.1817 -1.5815% AMZN 184.65 -2.6621% META 564.0 -3.0944% AVGO 173.83 -3.094% TSLA 213.45 -2.0737% TSM 199.38 0.4534% LLY 899.58 -1.0526% V 284.49 -0.1053% JPM 224.22 0.0446% UNH 566.27 -0.63% NVO 115.65 -0.704% WMT 83.22 1.4631% LVMUY 131.53 -1.5789% XOM 119.905 -0.6587% LVMHF 660.0 -1.3099% MA 513.84 0.1598%

Emmaus Life Sciences Inc

Healthcare US EMMA

0.025USD
-0.0109(30.36%)

Last update at 2024-10-23T13:30:00Z

Day Range

0.030.03
LowHigh

52 Week Range

0.090.59
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap5.90M
  • Volume3000
  • P/E Ratio-
  • Dividend Yield5.18%
  • EBITDA0.81M
  • Revenue TTM28.46M
  • Revenue Per Share TTM0.55
  • Gross Profit TTM 17.30M
  • Diluted EPS TTM-0.08

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.62500M -15.92100M -54.67800M -54.67800M -10.33120M
Minority interest - - - - -0.09709M
Net income -10.68500M -15.94600M -54.84200M -54.84200M -9.59870M
Selling general administrative 13.17M 13.44M 17.01M 17.01M 7.36M
Selling and marketing expenses 7.49M 5.88M 6.97M 6.97M 1.99M
Gross profit 15.80M 17.30M 21.66M 21.66M 0.49M
Reconciled depreciation 0.05M 0.06M 0.06M 0.07M 0.12M
Ebit -6.63900M -6.12800M -4.51200M -27.28500M -10.24490M
Ebitda -6.58600M -8.04100M -8.19400M -27.21200M -10.12700M
Depreciation and amortization 0.05M -1.91300M -3.68200M 0.07M 0.12M
Non operating income net other - - -3.83000M -3.83000M -
Operating income -6.58600M -6.12800M -4.51200M -4.51200M -10.24490M
Other operating expenses 24.98M 26.74M 27.26M 27.26M 11.56M
Interest expense 5.01M 3.10M 27.39M 27.39M 0.09M
Tax provision 0.06M 0.03M -0.38100M 0.16M 0.00190M
Interest income 0.68M 0.76M 2.30M - -
Net interest income -4.33300M -2.34000M -3.68600M -27.39300M -0.08630M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.06M 0.03M 0.16M 0.16M 0.00190M
Total revenue 18.39M 20.61M 22.75M 22.75M 1.32M
Total operating expenses 22.39M 23.43M 26.17M 26.17M 10.73M
Cost of revenue 2.59M 3.31M 1.09M 1.09M 0.83M
Total other income expense net -4.03900M -9.79300M -50.16600M -50.16600M -0.08630M
Discontinued operations - - - - -
Net income from continuing ops -10.62500M -15.94600M -54.84200M -54.84200M -10.33310M
Net income applicable to common shares - -15.94600M -54.84200M -54.84200M -72.58700M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 48.23M 56.73M 59.46M 59.46M 5.15M
Intangible assets - - - - 0.12M
Earning assets - - - - -
Other current assets 1.51M 0.39M 1.40M 1.40M 0.19M
Total liab 82.32M 78.18M 70.51M 70.51M 1.87M
Total stockholder equity -34.09100M -21.45000M -11.05300M -11.05300M 4.02M
Deferred long term liab - - - - -
Other current liab 15.82M 5.91M 5.79M 10.01M 0.66M
Common stock 0.05M 0.05M 0.05M 0.05M 0.00740M
Capital stock 0.05M 0.05M 0.05M 0.05M 0.00850M
Retained earnings -252.33700M -241.26600M -226.22900M -226.22900M -85.24530M
Other liab - 33.17M 34.47M 33.75M 36.49M
Good will - - - - 1.39M
Other assets - 0.29M 0.30M 0.28M 0.41M
Cash 2.02M 2.28M 1.77M 1.77M 3.25M
Cash and equivalents - - - - -
Total current liabilities 54.32M 37.10M 32.83M 32.83M 1.17M
Current deferred revenue 10.00M 6.61M 4.22M - 0.16M
Net debt 23.08M 27.64M 17.71M 17.71M -2.66360M
Short term debt 24.72M 22.00M 15.54M 15.54M 0.00130M
Short long term debt 23.84M 21.26M 11.00M 14.55M 11.25M
Short long term debt total 25.10M 29.91M 19.48M 19.48M 0.59M
Other stockholder equity 220.81M 220.02M 215.21M 215.21M 89.26M
Property plant equipment - 3.63M 0.15M 0.15M 0.15M
Total current assets 6.29M 9.09M 41.22M 41.22M 3.51M
Long term investments 18.83M 17.62M 15.66M 13.32M 0.00000M
Net tangible assets - -21.45000M -11.05300M -11.05300M -21.70800M
Short term investments -19.97100M - 27.93M 27.93M 49.34M
Net receivables 0.38M 1.04M 2.15M 2.15M 0.06M
Long term debt 3.73M 4.65M 3.15M - 0.59M
Inventory 2.38M 4.39M 7.97M 7.97M 4.71M
Accounts payable 3.79M 2.58M 7.28M 7.28M 0.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.61900M -0.25500M -0.07900M -0.07900M -
Additional paid in capital - - - - -
Common stock total equity - - 0.05M 0.05M -
Preferred stock total equity - - - - -
Retained earnings total equity - - -226.22900M -226.22900M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.26M 26.39M 0.28M 0.28M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 41.94M 47.64M 18.23M 18.23M 1.64M
Capital lease obligations 3.26M 4.00M 4.61M 4.92M 0.00340M
Long term debt total - - 3.15M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.38700M -6.37700M 0.22M 0.22M -7.34600M
Change to liabilities 0.00000M 2.06M 9.34M 9.34M 3.57M
Total cashflows from investing activities - -6.37700M -1.48400M -1.48400M -7.44000M
Net borrowings - 7.41M -4.89100M -4.89100M 4.30M
Total cash from financing activities 7.23M 7.41M 3.88M 3.88M 7.21M
Change to operating activities - 0.46M -2.23100M -2.52400M 4.35M
Net income -10.62500M -15.94600M -54.84200M -54.84200M -10.33310M
Change in cash -0.25800M -0.20800M -2.13600M -2.13600M -2.19430M
Begin period cash flow 2.28M 2.49M 3.90M 3.90M 5.45M
End period cash flow 2.02M 2.28M 1.77M 1.77M 3.25M
Total cash from operating activities -5.07300M -1.25400M -4.52300M -4.52300M -9.03868M
Issuance of capital stock - 0.00000M 0.14M 8.59M 2.97M
Depreciation 0.05M 0.06M 0.07M 0.07M 0.12M
Other cashflows from investing activities - -6.30400M -1.64500M -1.64500M -3.95600M
Dividends paid - - - - -
Change to inventory 0.43M 0.46M -3.26700M -3.26700M -0.09150M
Change to account receivables 0.61M -0.84500M -0.36100M -0.36100M -0.00050M
Sale purchase of stock - - 8.78M 8.78M -
Other cashflows from financing activities 10.37M 16.19M 0.79M 0.79M 6.35M
Change to netincome 1.48M 10.71M 3.95M 3.95M 46.55M
Capital expenditures 0.03M 0.07M 0.06M 0.06M 0.06M
Change receivables - - -0.36100M -0.36100M -
Cash flows other operating - - 16.81M 16.81M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -2.12300M -2.12300M -
Change in working capital 2.21M 2.11M 0.31M 0.31M -0.69680M
Stock based compensation 0.02M 0.55M 3.81M 3.81M 1.59M
Other non cash items 3.27M 2.31M 27.12M 46.13M 0.28M
Free cash flow -5.09900M -1.32700M -4.58300M -4.58300M -9.09388M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EMMA
Emmaus Life Sciences Inc
-0.0109 30.36% 0.03 - - 0.21 - 1.40 19.49
NVO
Novo Nordisk A/S
-0.82 0.70% 115.65 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-4.98 4.26% 112.02 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.04 1.27% 468.87 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-24.015 2.50% 938.33 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Emmaus Life Sciences Inc

21250 Hawthorne Boulevard, Torrance, CA, United States, 90503

Key Executives

Name Title Year Born
Dr. Yutaka Niihara M.D., M.P.H, M.P.H. Chairman & CEO 1960
Mr. Willis C. Lee M.S. Vice Chairman & COO 1960
Mr. Yasushi Nagasaki CPA, CPA Chief Financial Officer 1967
Mr. George Sekulich Sr. VP of Global Commercialization & Chief Information Officer 1966
Mr. Dale E. Short J.D. Gen. Counsel NA
Dr. Charles W. Stark Pharm.D, Pharm.D. Sr. VP of Medical Affairs, Clinical, Regulatory 1955
Mr. Kurt H. Kruger M.B.A., M.S. Consultant 1955
Mr. S. Steven Lee Independent Consultant 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.